Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
| Autor: | Toshihide Izumida, Emiri Muranaka, Yukio Kawagishi, Hiroshi Tsuji, Shinichi Takeda, Komugi Okeya |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
Lung Neoplasms medicine.medical_treatment Case Report Adenocarcinoma of Lung Pembrolizumab 030204 cardiovascular system & hematology Antibodies Monoclonal Humanized Small-cell carcinoma immune checkpoint inhibitors 03 medical and health sciences 0302 clinical medicine small-cell carcinoma Antineoplastic Agents Immunological Internal Medicine medicine Carcinoma Humans Lung cancer Aged Chemotherapy business.industry transformation General Medicine medicine.disease hyperprogressive disease Small Cell Lung Carcinoma Tumor progression Cancer research Adenocarcinoma 030211 gastroenterology & hepatology pembrolizumab business Progressive disease |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | Hyperprogressive disease (HPD) is a paradoxical phenomenon involving the acceleration of tumor progression after treatment with immune checkpoint inhibitors (ICIs). A 66-year-old male smoker with advanced lung adenocarcinoma started pembrolizumab for progressive disease following first-line chemotherapy. He developed HPD after two cycles, and a re-biopsy revealed transformation to small-cell carcinoma. He subsequently underwent two lines of chemotherapy for small-cell carcinoma until progression and ultimately died. Transformation to small-cell carcinoma may be a cause of HPD during ICI therapy. The possibility of pathological transformation should be considered in cases of HPD with resistance to ICI therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|